Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > How much is needed to start Phase I?
View:
Post by JoeyBoston on Aug 10, 2021 6:15pm

How much is needed to start Phase I?

Can someone with knowledge in this area please answer how much is needed to officially start the Phase I trial for PMN-310, with a detailed schedule, committment, etc.? I've seen numbers been thrown around in the past that vary widely from $10M to $30M. I'm guessing this is the big announcement that will move this stock to the next level. The capital needed will predict how it will be financed. I just cant see how Phase I could be funded with another retail PP, and that "bigger" investors will need to be involved.
Comment by Thenorth1990 on Aug 10, 2021 6:29pm
The following table provides an overview of the estimated expenditures required for the Company to advance its PMN310 monoclonal antibody into a clinical trial and, subject to approval of an IND application, complete Phase 1. The Company cautions readers that such information is forward-looking in nature and is qualified in its entirety by the risk factors and other disclosure set-out under “Risk ...more  
Comment by Mole101 on Aug 10, 2021 6:45pm
I'm wondering where is PMN with this or if it ever got of the ground as it was supposed to start as Covid -19 h began ... with Toronto Memory Program, Canada’s largest and most experienced memory clinic and site for drug treatment trials in Alzheimer’s disease (AD) has initiated a pilot longitudinal study to assess the level of blood-based biomarkers in early AD with the support of Parexel ...more  
Comment by Speyeder999 on Aug 10, 2021 8:25pm
Mole, you bring up an excellent point. What's the point in coming out with a  news release if you don't plan on giving an update at least once every 6-12 months. Case  in point: the Covid serology  test. Perhaps many here  are comfortable with the absence of news on this matter because it doesn't fall in the company's core field of research, but you'd think ...more  
Comment by Thenorth1990 on Aug 10, 2021 8:38pm
true , I dont think anyone here on the board is comfortable with shfting goal posts and keeping us in the dark. Its an excuse. but the only case I have for myself, i have been investing in this  since 2019 , and the company is in a much better poistion today and I am staying may be for another 1 year to see where this goes. I wish I could afford but I wont wait until the time, when pmn310 ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities